Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Melanoma, Neoplasm Metastasis

Breast Neoplasms

Anatomic Stage II Breast Cancer AJCC v8

Advanced Breast Carcinoma

Breast Neoplasms

Estrogen Receptor-positive Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8

Breast Neoplasms

Locoregional Recurrence

Salivary Gland Neoplasms

Adenocarcinoma of Endometrium

Breast Neoplasms

Malignant Neoplasms of Female Genital Organs

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Diarrhea, Exanthema

Ovarian Neoplasms

Breast Neoplasms

Breast Neoplasms

ER-Positive Breast Cancer

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Breast Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Brest Cancer

Breast Neoplasms

Ovarian Neoplasms, Endometrial Neoplasms

Adenoma, Islet Cell

Breast Neoplasms

Carcinoma, Lobular

Breast Neoplasms

Hormone Receptor Positive Breast Carcinoma

Breast Cancer Metastatic

Breast Neoplasms

Breast Cancer Metastatic

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Stomach Neoplasms, Carcinoma, Lobular, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Neoplastic Cells, Circulating

Clinical Trials

CAMERAN

Efficacy and Safety of 500mg of Fulvestrant

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

EPIBREAST

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

VS-6766+Abema+Fulv in Met HR+/HER- BC

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

FAIM

RaPhLRR

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

SAFE-CAP

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

PATINA

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

GERTRUDE

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NETHER

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

ABIGAIL

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

ITHRAN

ROLo

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Palbociclib After CDK and Endocrine Therapy (PACE)

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

SoGreat

ABC-SE